Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up

By C. Söderberg, P. Stål, J. Askling, H. Glaumann, G. Lindberg, J. Marmur, R. Hultcrantz. Hepatology, 2010

763 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/9dd7eda6e8043f821a3070b853306a33949b6829

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. G. Targher
3. Christopher D. Byrne
4. A. Lonardo
5. A. Baranova
6. G. Vernon
7. Megan H. Bair-Merritt
8. Herbert Tilg

In Epidemiology

1. Z. Younossi
2. G. Targher
3. Christopher D. Byrne
4. A. Lonardo
5. A. Baranova
6. Z. Goodman
7. Terry M. Therneau
8. G. Vernon

In Pathology and Forensic Medicine

1. Z. Younossi
2. Christopher D. Byrne
3. A. Baranova
4. G. Targher
5. G. Vernon

Citations in the corpus

• Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. (2016, background): “the more severe forms of NAFLD need particular attention to ameliorate their high risk of CVD events [5,33,45,46,50,55].”
• NAFLD: a multisystem disease. (2015, result): “Interestingly, some of these studies also reported that patients with NASH, but not those with simple steatosis, had [23,88] an increased risk of all-cause and CVD mortality compared with the reference population.”
• Association between Non-invasive Fibrosis Markers and Mortality among Adults with Non-alcoholic Fatty Liver Disease in the United States (2013, result): “Second, from this and other studies, it is clear that NAFLD without advanced fibrosis has little effect on mortality upon follow-up for up to two decades.(4,6,7,38) However, NAFLD with advanced fibrosis is an independent predictor of increased mortality, mainly from cardiovascular causes.”
• Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults (2011, background): “These investigators showed that mortality was increased in the NASH group but not in those with simple steatosis.(108)”
• Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (2011, background): “In summary, our data confirm that patients with NASH are at high risk for LRM.(1-14,21-30) We have also shown that a certain degree of agreement exists between all four sets of pathologic criteria for NASH.”
• Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up (2015, methodology): “In two previous follow-up studies, 113 of the included NAFLD patients were tested for hepatitis C, and none tested positive.(21,22) Three patients were excluded after reviewing their medical charts because they had tested positive for hepatitis C.”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, neutral): “Recent studies in tertiary-care centers, using current histological definitions, have shown a surprisingly high prevalence of NASH among NAFLD cases: 43–55% in patients with increased aminotransferases [21,22], as high as 49% in morbidly obese patients [23,24], and 67% in a subset of patients with i”
• Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. (2017, background): “NAFLD patients have an increased all-cause and liver related mortality [8, 9].”